Tag: Adjuvanted vaccine
-
CSL Seqirus Highlights 14 Abstracts at ESWI 2025: Advancing Enhanced Seasonal Influenza Vaccines
CSL Seqirus to Present 14 Abstracts at ESWI 2025 CSL Seqirus, a global leader in influenza vaccines, announced it will present 14 abstracts at the European Scientific Working group on Influenza (ESWI) conference, taking place in Valencia from 20 to 23 October 2025. The presentations highlight the value of enhanced seasonal influenza vaccines and reinforce…
-
CSL Seqirus Highlights 14 ESWI Abstracts on Enhanced Seasonal Influenza Vaccines
CSL Seqirus to Present 14 Abstracts at ESWI 2025 CSL Seqirus, part of CSL (ASX: CSL), announced today that it will present 14 abstracts at the European Scientific Working group on Influenza (ESWI) conference, taking place October 20–23 in Valencia, Spain. The presentations underscore the value of enhanced seasonal influenza vaccines and reinforce their critical…
-
Fluad for 65+ — An Enhanced Adjuvanted Flu Vaccine for Seniors
What Fluad is and who should consider it Fluad is an enhanced trivalent influenza vaccine that contains an adjuvant. In France, the Haute Autorité de Santé (HAS) recommends Fluad for people aged 65 years and older, as a preferential choice for protection against seasonal flu. The HAS considers adjuvanted vaccines like Fluad to be a…
-
Fluad: An Adjuvanted Flu Vaccine for People 65 and Older
Fluad and the Protection of Seniors (65+) Against Influenza Fluad is an enhanced adjuvanted, trivalent influenza vaccine that France’s Haute Autorité de Santé (HAS) recommends preferentially for adults aged 65 and older. In practice, HAS regards adjuvanted vaccines like Fluad as offering protection comparable to high-dose vaccines such as Efluelda, and it positions them as…